SSR 180575

Drug Profile

SSR 180575

Alternative Names: [11C]-SSR180575; SSR180575

Latest Information Update: 16 Jul 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator sanofi-aventis
  • Developer Sanofi; sanofi-aventis
  • Class Acetamides; Heart failure therapies; Indoles; Neuroprotectants; Small molecules
  • Mechanism of Action TSPO protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported CNS disorders; Heart failure; Neurodegenerative disorders; Rheumatic disorders
  • Discontinued Diabetic neuropathies

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Neurodegenerative-disorders(Diagnosis, Early-stage disease) in France (IV, Injection)
  • 29 Apr 2009 Discontinued - Phase-II for Diabetic neuropathies in USA (PO)
  • 12 Dec 2005 Data presented at the 35th Annual Meeting of the Society for Neuroscience (SfN-2005) have been added to the Neurological disorders pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top